Pemigatinib

Unassigned

New Medicines

Intrahepatic cholangiocarcinoma with fibroblast growth factor receptor rearrangements

Information

New molecular entity
Incyte
Incyte

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Inhibitor of fibroblast growth factor receptor (isoforms 1 2 and 3).
Cholangiocarcinoma arises from the cells within the bile ducts. It is often diagnosed late (stages III and IV) and the prognosis is poor. It is most common in those over 70 years old and is more common in men than women [1]. Incidence is 1-2 per 100,000 population per year in the UK [2].
Intrahepatic cholangiocarcinoma with fibroblast growth factor receptor rearrangements
Oral